Human Vasodilatory Effect of GLP-1

Comprehensive assessment of human vasodilatory effect of GLP-1 in forearm and coronary arteries

Completed

Looking for future studies?

Key information

Conditions

Coronary Stenosis Angina Pectoris Angina, Stable Cardiovascular Diseases Chest Pain Coronary Disease Heart Diseases Myocardial Ischemia Neurologic Manifestations Pain Pathological Conditions, Signs and Symptoms Signs and Symptoms Type2 Diabetes Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Waiting list for elective PCI to LAD Able to give informed consent Over 18

Exclusion criteria

GLP-1 based therapy Insulin Calcium channel blockers Nicorandil Nitrates

Treatment and study plan

GLP-1 (7-36)Amide

Drug

IV infusion

Primary outcomes

Change in IMR (index of microcirculatory resistance) with GLP-1 compared with baseline

Time frame: Change from baseline

Change in coronary microcirculatory resistance from baseline
Forearm bloodflow ratio with GLP-1

Time frame: Change from baseline

Peripheral vasodilatory response of GLP-1

Sponsors and collaborators

Lead sponsor

Papworth Hospital NHS Foundation Trust

Other Gov

Registry information

Official study title

Vasodilatory Effect of GLP-1

Important dates

Study start: 2015
Primary completion: 2017
Study completion: 2017
First posted: Apr 18, 2018
Registry last updated: Apr 18, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed